中国妇幼健康研究2025，Vol.36Issue(3)：79-84,6.DOI:10.3969/j.issn.1673-5293.2025.03.012
血清sCD163、CCL18表达在支气管哮喘患儿病情监测及预后预测中的价值
Clinical values of serum sCD163 and CCL18 expressions for evaluating disease severity and predicting prognosis of children with bronchial asthma
摘要
Abstract
Objective To investigate clinical values of expression levels of soluble cluster differentiation 163(sCD163)and CC chemokine ligand 18(CCL18)in serum for evaluating severity of bronchial asthma(BA)and predicting prognosis of the children with BA.Methods 120 children with BA who admitted to our hospital from January 2021 to January 2022 were selected as BA group.According to severity of the disease,they were divided into mild BA group(34 cases),moderate BA group(62 cases),and severe BA group(24 cases).Again,according to prognosis,the children in the BA group were divided into good prognosis group(52 cases)and poor prognosis group(68 case).A total of 120 healthy children who underwent physical examination in the same period were randomly selected as the control group.ELISA was applied to detect serum levels of sCD163 and CCL18,and pulmonary function test apparatus was applied to test percentage of peak expiratory flow(PEF)and forced expiratory volume in one second(FEV1)of the children.Pearson correlation analysis was used to analyze correlation between sCD163 and CCL18.Multivariate Logistic regression was applied to analyze influencing factors of poor prognosis of the children with BA.ROC curve was applied to evaluate predictive values of CD163 and CCL18 for poor prognosis of the children with BA.Results The serum levels of sCD163 and CCL18 of BA children were higher than those in the control group,while their PEF and FEV1 were lower than those in the control group,and the differences were significant(t values were between 8.082 and 10.896,all P＜0.05).And the serum levels of sCD163 and CCL18 of BA children in the mild BA group,the moderate BA group and the severe BA group increased successively along with increase in severity of the disease,and the differences were significant(F=14.378 and 38.191 respectively,both P＜0.05).The serum levels of sCD163 and CCL18 of the children with BA in the good prognosis group were significantly lower than those in the poor prognosis group,while their PEF and FEV1 were significantly higher than those in the poor prognosis group(T values were between 5.576 and 8.295,all P＜0.05).Logistic regression analysis showed that the expression levels of sCD163 and CCL18 in serum were independent risk factors for poor prognosis of these children with BA(OR=1.587 and 1.826 respectively,both P＜0.05),while PEF and FEV1 were independent protective factors for poor prognosis of these children with BA(OR=0.527 and 0.425 respectively,both P＜0.05).Pearson correlation analysis showed that in the poor prognosis group the serum expression level of sCD163 was positively correlated with the serum expression level of CCL18(r=0.485,P＜0.001).The AUCs of sCD163,CCL18 and their combination for predicting poor prognosis of these children with BA were 0.825(95％CI:0.752-0.897),0.841(95％CI:0.774-0.909)and 0.906(95％CI:0.856-0.955)respectively,indicating that the combied prediction of the two indexes was superior to those of their single prediction(Z=2.454 and 2.779 respectively,both P＜0.05).Conclusion In these children with BA,as severity of BA increases,the expression levels of sCD163 and CCL18 in serum gradually increase.The combination of sCD163 and CCL18 has high value for predicting poor prognosis of BA children,so they can be used as early diagnostic indicators of the disease.关键词
支气管哮喘/患儿/可溶性血红蛋白清道夫受体163/CC趋化因子配体18/预后Key words
bronchial asthma/children/soluble cluster differentiation 163/CC chemokine ligand 18/prognosis分类
医药卫生引用本文复制引用
王艳茹,王强,冯涛,杜桂梅..血清sCD163、CCL18表达在支气管哮喘患儿病情监测及预后预测中的价值[J].中国妇幼健康研究,2025,36(3):79-84,6.基金项目
2023年度河北省医学科学研究课题(20232077) （20232077）
